Robert J. Talbert MD, Presenter: Nothing to Disclose

Chris R. Smith MD, Abstract Co-Author: Nothing to Disclose

Michael V. Friedman MD, Abstract Co-Author: Nothing to Disclose

Travis J. Hillen MD, Abstract Co-Author: Consultant, Biomedical Systems Consultant, Vidacare Corporation

Jonathan Craig Baker MD, Abstract Co-Author: Research Consultant, Biomedical Systems

1. Computed tomography (CT)-guidance for percutaneous biopsy of musculoskeletal lesions remains the gold standard imaging modality for biopsy of musculoskeletal lesions, particularly osseous lesions. 2. Typically, most suspicious lesions have an identifiable CT correlate and biopsy can be easily targeted to the lesion of interest. However, with the increasing use of positron emission tomography-CT (PET/CT) and MRI for the surveillance and staging of cancer, suspicious lesions necessitating biopsy are sometimes identified which have no CT correlation. 3. Although PET/CT- and MR-guided biopsies are technically feasible, they are not without limitation or entirely necessary. Rather, these lesions, even if CT-occult, can often be biopsied with CT-guidance using anatomic landmarks for lesion targeting.  

1. Common etiologies of suspicious CT-occult lesions. 2. Limitations of PET/CT- and MR-guided biopsy. 3. General CT-guided biopsy technique. 4. Biopsy of CT-occult lesions using anatomic landmarks.         a. Useful landmarks.           b. Specific examples (sample of cases in PDF submission).           c. Limitations.  

http://abstract.rsna.org/uploads/2014/14009362/14009362_n3s1.pdf

Talbert, R, Smith, C, Friedman, M, Hillen, T, Baker, J, The Not-So-Obvious: CT-guided Biopsy of CT-occult Musculoskeletal Lesions.  Radiological Society of North America 2014 Scientific Assembly and Annual Meeting, - ,Chicago IL. http://archive.rsna.org/2014/14009362.html